Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALA - KALA BIO, Inc.


Previous close
7.05
-0.010   -0.142%

Share volume: 200
Last Updated: Fri 27 Dec 2024 05:20:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.40%

PREVIOUS CLOSE
CHG
CHG%

$7.06
-0.01
-0.14%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 18%
Dept financing 21%
Liquidity 73%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
4.00%
1 Month
-3.83%
3 Months
18.86%
6 Months
35.65%
1 Year
-18.00%
2 Year
59.18%
Key data
Stock price
$7.05
P/E Ratio 
-3.12
DAY RANGE
$7.06 - $7.16
EPS 
-$4.55
52 WEEK RANGE
$4.79 - $9.25
52 WEEK CHANGE
-$16.02
MARKET CAP 
26.955 M
YIELD 
N/A
SHARES OUTSTANDING 
4.608 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,437
AVERAGE 30 VOLUME 
$29,205
Company detail
CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.

Recent news